A retrospective, multicenter study to determine tumour-infiltrating lymphocytes association with the outcome for ICIs and for chemotherapy in advanced non-small cell lung cancer patients
Latest Information Update: 04 Feb 2021
At a glance
- Drugs Nivolumab (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Feb 2021 New trial record
- 27 Jan 2021 Primary endpoint (overall survival) has not been met.
- 27 Jan 2021 Results published in the European Journal of Cancer